Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $80
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $95 to $80.
Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $95 to $80.